Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.L. Fernández Soto, A. González Jiménez, M.M. Campos Pastor, M.C. Vela Maroto, F. Escobar-Jiménez.
Estudio y seguimiento de tiroglobulina, anticuerpos antitiroglobulina y sensibilización celular in vitro en la evolución y tratamiento de la enfermedad de Graves.
Endocrinología, 34 (1987), pp. 199-202
[2.]
M.L. Fernández Soto, A. González Jiménez, A. Maroto Vela, F. Escobar-Jiménez.
Azatioprina en el tratamiento de la oftalmopatía asociada a enfermedad de Graves.
Endocrinología, 37 (1990), pp. 269-273
[3.]
M.M. Campos Pastor, M.L. Fernández Soto, F. Escobar-Jiménez, F. Barredo Acedo, M. Ruiz de Almodóvar.
Evolución inmunológica y de la función tiroidea a largo plazo en la enfermedad de Graves según distintas opciones terapéuticas.
Med Clin (Barc, 102 (1994), pp. 446-450
[4.]
M.L. Fernández Soto, F. Escobar Jiménez, A. González Jiménez, F. Sánchez Franco.
Diagnóstico y tratamiento de la Enfermedad de Graves. Resultados de una encuesta Nacional en 1987.
Endocrinología, 35 (1988), pp. 166-174
[5.]
F. Escobar-Jiménez, M.L. Fernández Soto.
Enfermedad tiroidea autoinmune: implicación en el embarazo y posparto [editorial].
Endocrinología, 38 (1991), pp. 133-135
[6.]
A. González Jiménez, M.L. Fernández Soto, F. Escobar-Jiménez, D. Glinoer, L. Navarrete.
Thyroid function parameters and TSH-receptor antibodies in healthy subjects and Graves’ disease patients: a sequential study before, during and after pregnancy.
Thyroidology, 5 (1993), pp. 13-20
[7.]
M.L. Fernández Soto, L.G. Jovanovic, A. González Jiménez, J.A. Hernández Lobón, F. Escobar-Jiménez, L. Navarrete, et al.
Thyroid function during pregnancy and the postpartum period: iodine metabolism and disease states.
Endocrine Practice, 4 (1998), pp. 97-105
[8.]
M.L. Fernández Soto, A. González, J.A. Lobón, J.A. López, C.M. Petterson, F. Escobar-Jiménez.
Thyroid peroxidase autoantibodies predict poor metabolic control and need for thyroid teatment in pregnant IDDM women.
Diabetes Care, 20 (1997), pp. 1524-1528
[9.]
M.M. Pastor Campos, M.E. Muñoz Torres, F. Escobar-Jiménez, M. Ruiz de Almodóvar, E. Jódar Gimeno.
Bone mass in females with different thyroid disorders: influence of menopausal status.
Bone Miner, 21 (1993), pp. 1-8
[10.]
G.J. Kahaly.
Cardiovascular and atherogenic aspects of subclinical hypothyroidism.
Thyroid, 10 (2000), pp. 665-679
[11.]
E. Phelps, W. Peiging, J. Bretz, J.R. Baker.
Thyroid cell apoptosis: a new understanding of thyroid autoimmunity. En: Autoimmune thyroid disease.
Endocrinol Metabol Clin North Am, 29 (2000), pp. 375-388
[12.]
M.L. Fernández Soto, A. González, F. Escobar-Jiménez, R. Vázquez, E. Ocete, N. Olea, et al.
Increeased risk of autoinmune thyroid disease in hepatitis C vs hepatitis B before, during and after discontinuing interferon therapy.
Arch Intern Med, 159 (1998), pp. 1445-1448
[13.]
M.L. Fernández Soto, M. Ventosa Viña, V. Luna, F.J. Escobar Salmerón.
Hipotiroidismo permanente tras tratamiento con interferón-??en la hepatitis crónica C.
Med Clin (Barc, 107 (1996), pp. 46-47
[14.]
M.L. Fernández-Soto, A. González-Jiménez, F. Escobar-Jiménez.
Smoking and autoimmune thyroid disease.
Ann Intern Med, 126 (1997), pp. 1005
[15.]
M.L. Fernández Soto, M.M. Campos Pastor, A. González Jiménez, F. Barredo Acedo, R. Ruiz Acedo, F. Escobar-Jiménez.
Identidad entre anticuerpos antiperoxidasa y microsomales: estudio en enfermedad autoinmune órgano específica.
Endocrinología, 38 (1991), pp. 3-9
[16.]
M.L. Fernández Soto, M.M. Campos, A. González, F. Barredo, N. Olea, F. Escobar-Jiménez.
Anticuerpos antiperoxidasa: estudio en sujetos sanos y con enfermedad tiroidea autoinmune.
Endocrinología, 42 (1995), pp. 75-78
[17.]
F. Escobar-Jiménez, M.L. Fernández Soto, V. Luna López, M. Quesada Charneco, D. Glinoer.
Trends in diagnostic and therapeutic criteria in Graves, Endocrinol Metabel Clin North Am disease in the last ten years.
Postgrad Med J, 76 (2000), pp. 0-4
[18.]
R.A. Ajjan, C. Findlay, R.A. Metcalfe, P.F. Watson, R.S. McIntosh.
The modulation of the human sodium iodide symporter activity by Graves, disease sera.
J Clin Endocrinol Metab, 83 (1998), pp. 1217-1223
[19.]
P.A. Smakik, Q. Lin, T.L. Furminger, K.Y. Ryn, K.S. Theil.
Cloning of the human sodium iodide symporter.
Biochem Biophs Res Commun, 226 (1996), pp. 339-343
[20.]
R. Paschke, M. Ludgate.
Thyrotropin-receptor in thyroid diseases.
N Engl J Med, 337 (1997), pp. 1675-1681
[21.]
S. Kubota, K. Gunji, B.A.C. Ackrell, B. Cochran, C. Stolarski, S. Wengrowicz, et al.
The 64-Kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good marker of an immune mediated damage to the eye muscle in patients with Graves, hyperthyroidism.
J Clin Endocrinol Metab, 83 (1998), pp. 443-447
[22.]
M.P.J. Vanderpump, W.M.S. Tunbridge, J.M. French, D. Appleton, D. Bates, F. Clark, et al.
The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey.
Clin Endocrinol, 43 (1995), pp. 55-68
[23.]
T.F. Davies, N. Amino.
A new classification for human autoimmune thyroid disease.
Thyroid, 3 (1993), pp. 331-333
[24.]
D. Robert, M.D. Utiger.
Vanishing hypothyroidism.
N Engl J Med, 326 (1992), pp. 562-563
[25.]
R. Comtois, L. Faucher, L. Lafléche.
Outcome of hypothyroidism caused by Hashimoto,s thyroiditis.
Arch Intern Med, 155 (1995), pp. 1404-1408
[26.]
K. Sato, K. Okamura, T. Hirata, K. Yamasaki, H. Ikenoue, T. Kuroda, et al.
Immunological and chemical types of reversible hypothyroidism; clinical characteristics and long-term prognosis.
Clin Endocrinol, 45 (1996), pp. 519-528
[27.]
J. Tajari, K. Higashi, M. Morita, T. Umeda, T. Sato.
Studies of hypothyroidism in patients with high iodine intake.
J Clin Endocrinol Metab, 63 (1986), pp. 412
[28.]
P.D. Woolf.
Transient painless thyroiditis with hyperthyroidism: a variant of lymphocytic thyroiditis?.
Endocrine Rev, 1 (1980), pp. 411-420
[29.]
K. Okamura, K. Sato, M. Yoshinari, H. Ikenoue, T. Kuroda, M. Nokagawa, et al.
Recovery of the thyroid function in patients with atrophic hypothyroidism and blocking type TSH binding inhibitor immunoglobulin.
Acta Endocrinol (Copenh, 102 (1990), pp. 46-48
[30.]
N. Takasu, T. Yamada, M. Takasu, I. Komiya, Y. Nagasawa, T. Asawa, et al.
Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis.
N Engl J Med, 326 (1992), pp. 513-518
[31.]
T. Yamamoto, H. Sakamoto.
Spontaneous remission from primary hypothyroidism.
An Intern Med, 88 (1978), pp. 808-809
[32.]
K. Okamura, K. Sato, H. Ikenone, M. Yoshinari, M. Nakagawa, T. Kuroda, et al.
Reevaluation of the thyroidal radioactive iodine uptake test, with special reference to reversible primary hypothyroidism with elevated thyroid radioiodine uptake.
J Clin Endocrinol Metab, 67 (1988), pp. 720-726
[33.]
K. Sato, K. Okamura, H. Ikenoue, A. Shiroozu, M. Yoshinari, M. Fujishima.
TSH dependent elevation of serum thyroglobulin in reversible primary hypothiroidism.
Clin Endocrinol, 29 (1988), pp. 231-237
[34.]
M. Yoshinari, K. Okamura, T. Tokayama, A. Shiroozu, T. Nakashima, K. Inoue, et al.
Clinical importance of reversibility in primary goitrous.
Br Med J, 287 (1983), pp. 720-722
[35.]
M.D. Serrano Pardo.
Universidad de Granada, (1999),
[36.]
D.V. Harbour.
The hormones of the hypothalamic-pituitary-thyroid axis and their receptors in the immune system.
Adv Neuroimmunol, 1 (1991), pp. 204-213
[37.]
T.E. Kruger, L.R. Smith, D.V. Harbour, J.E. Blalock.
Thyrotropin and endogenous regulator of the in vitro immune response.
J Immunol, 142 (1989), pp. 744-747
[38.]
L. Chiovato, P. Vitti, A. Lombardi, L.D. Kohn, A. Pinchera.
Expression of the microsomal antigen on the surface of continuously cultured rat thyroid cells is modulated by thyrotropin.
J Clin Endocrinol Metab, 61 (1985), pp. 12
[39.]
K. Hashizume, M. Kobayashi.
Thyroid hormone inhibition of biosynthesis of protein inhibitors for S-adenosyl-L-methionine-mediated methylation of phosphatidylethanolamine in rat liver [resumen].
[40.]
K. Hashizume, K. Yamauchi, M. Kobayashi, T. Miyamoto.
Thyroid hormone inhibition of phosphatidylinositol-specific phospholipase C in rat liver.
Endocrinol Jpn, 32 (1985), pp. 481-487
[41.]
E. Nystrom, P.A. Lundberg, G. Lindstedt.
Rebound increase in serum thyrotropin, antimicrosomal antibodies and thyroglobulin after discontinuation of L-thyroxine.
J Intern Med, 228 (1990), pp. 497-501
[42.]
M. Rieu, A. Richard, M. Rosilio, S. Laplandre, V. Ropion, J.P. Fombeur, et al.
Effects of thyroid status on thyroid autoimmunity expression in euthyroid and hypothyroid patients with Hashimoto,s thyroiditis.
Clin Endocrinol, 40 (1994), pp. 529-535
[43.]
J.H. Romaldini, M.M. Biancalana, D.L. Figueiredo, C.S. Farah, P.C. Mathias.
Effect of L-thyroxine administration on antithyroid antibody levels, lipid profile, and thyroid volume in patients with Hasimoto,s thyroiditis.
Thyroid, 6 (1996), pp. 183-188
[44.]
N. Takasu, I. Komiya, T. Asawa, Y. Nagasawa, T. Yamada.
Test for recovery from hypothyroidism during thyroxine therapy in Hashimoto’s thyroiditis.
Lancet, 3 (1990), pp. 1084-1087
[45.]
Y. Hayashi, H. Tamai, S. Fakata, Y. Hirota, S. Katayama, K. Kuma, et al.
A long-term clinical, immunological and histological follow-up study of patients with goitrous chronic lymphocytic thyroiditis.
J Clin Endocrinol Metab, 61 (1985), pp. 1172-1178
[46.]
P.D. Papapetrou, J.M. Lazarus, R.N.M. McSween, R. Harden.
Long-term treatment of Hashimoto,s thyroiditis with thyroxine.
Lancet, 2 (1972), pp. 1045-1048
[47.]
W. Reinhardt, T.L. Paul, E.M. Allen, S. Alex, Y.N. Yang, M.C. Appel, et al.
Effect of L-thyroxine administration and the incidence of iodine induced and spontaneous lymphocytic thyroiditis in the BB/w rat.
Endocrinology, 122 (1988), pp. 1179-1181
[48.]
I. Todd, R. Pujol-Borrell, A. Belfiore, G.F. Bottazzo.
Thyrocyte HLA class II expression and regulation in relation to thyroid autoimmunity.
Acta Endocrinol (Copenh, 281 (1987), pp. 27-34
[49.]
G. Kroemer, I.M. De Alboran, J.A. Gonzalo, C. Martínez.
Immunoregulation by cytokines.
Crit Rev Immunol, 13 (1993), pp. 163-191
[50.]
H. Imura, J. Fukata, T. Mori.
Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems.
Clin Endocrinol (Oxf, 35 (1991), pp. 107-115
[51.]
M.B. Atkins, M.M. Kaplan, P.A. Demchak, S. Reichlin, J.W. Mier.
Thyroid dysfunction after high-dose interleukin-2 therapy: An update.
Autoimmune thyroiditis. Approaches towards its etiological differentiation, pp. 271-283
[52.]
S. Matsubayashi, F. Akasu, Y. Kasuga, C. Jamieson, R. Volpe.
Interleukin- 2 activated killer cells do not mediate autologous thyrocyte lysis in autoimmune thyroid disease in vitro.
Thyroid, 1 (1991), pp. 151-156
[53.]
K. Nakanishi, Y. Taniguchi, Y. Ohta.
Increased soluble interleukin 2 receptor levels in autoimmune thyroid disease.
Acta Endocrinol (Copenh, 125 (1991), pp. 253-258
[54.]
G. Kroemer, C. Francese, C. Martínez.
The role of IL-2 in the development of autoimmune thyroiditis.
Int Rev Immunol, 9 (1992), pp. 107-123
[55.]
N.P. Sauter, M.B. Atkins, J.W. Mier, R.M. Lechan.
Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after IL-2 and IFN- ??therapy for metastatic carcinoma: a case report.
Am J Med, 92 (1992), pp. 441-444
[56.]
R. Volpe.
The role of cytokines in the development of autoimmune thyroid disease.
Thyroid, 3 (1993), pp. 177-178
[57.]
K. Sato, K. Yamazaki, K. Shizume, Y. Yamakawa, T. Satoh, H. Demura, et al.
Pathogenesis of autoimmune hypothyroidism induced by limphokine- Activated Killer (LAK) cell therapy: In vitro inhibition of human thyroid function by interleukin-2 in the presence of autologous intrathyroidal lymphocytes.
Thyroid, 3 (1993), pp. 179-188
[58.]
Y. Hiroka, M. Kayama, S. Ohga, M. Kimura, M. Hasegawa, K. Shin, et al.
Deregulated production of IL-4 in autoimmune thyroid disease assayed with a new radioimmunoassay.
Clin Chim Acta, 216 (1993), pp. 1-10
[59.]
L. Bartalena, S. Brogionis, L. Grasso, E. Martino.
Interleukin-6 and the thyroid.
Eur J Endocrinol, 132 (1995), pp. 386-393
[60.]
A. Rasmussen Krogh, U. Feldt-Rasmussen, K. Bendtzen.
The effect of interleukin-1 on the thyroid gland.
Autoimmunity, 16 (1993), pp. 141-148
[61.]
B. Grubeck-Loebenstein, B. Buchan, D. Chantry, H. Kassal, M. Londei, K. Pirich, et al.
Analysis of intrathyroidal cytokine production in thyroid autoimmune disease: thyroid follicular cells produce interleukin-1 and interleukin-6.
Clin Exp Immunol, 77 (1989), pp. 324-330
[62.]
L. Bartalena, S. Brogionis, L. Grasso, E. Martino.
Increased serum interleukin- 6 concentration in patients with subacute thyroiditis: relationship with concomitant changes in serum T4-binding globulin concentration.
J Endocrinol Invest, 16 (1993), pp. 213-218
[63.]
L. Bartalena, S. Brogionis, L. Grasso, T. Rago, P. Vitti, A. Pinchera.
Interleukin- 6: a marker of thyroid-destructive processes?.
J Clin Endocrinol Metab, 79 (1994), pp. 1424-1427
[64.]
M. Salvi, G. Girasole, M. Pedrazzoni, M. Passeri, N. Giuliani, R. Minelli, et al.
Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves, disease.
J Clin Endocrinol Metab, 81 (1996), pp. 2976-2979
[65.]
J.J. Corrales, A. Orfao, A. López, M.T. Mories, J.M. Miralles, J. Ciudad.
Analysis of IL-2 and IL-6 binding to peripheral blood lymphocytes in Graves disease: relationship with disease activity.
Cytometry, 30 (1997), pp. 118-123
[66.]
A. Loviselli, M.A. Calia, S. Murenu, P. Mossa, M.A. Cambosu, A. Caradonna.
Circulating soluble IL-2 receptor levels are low in patients with hypothyroid autoimmune thyroiditis.
Horm Metab Res, 26 (1994), pp. 548-551
[67.]
L. Ahmad, A. Parkes, J. Lazarus, L. Bartalena, E. Martino, E. Diamond, et al.
Interleukin-6 levels are not increased in women with postpartum thyroid dysfunction.
Thyroid, 8 (1998), pp. 371-375
Copyright © 2001. Sociedad Española de Endocrinología y Nutrición